COMMUNIQUÉS West-GlobeNewswire

Genmab Announces Data to be Presented at 2018 ASCO Annual Meeting
25/04/2018
Media Release 11 industry sponsored abstracts regarding Genmab programs scheduled for presentation at ASCO Annual Meeting One oral presentation, three poster discussion sessions and seven poster presentations Copenhagen [...]
BioSyent to Present at Upcoming Investor Conferences
25/04/2018
TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) is pleased to announce that it will be presenting at the following upcoming investor conferences: May 2, 2018 - Bloom Burton & [...]
CV Sciences, Inc. Fully Retires Convertible Debt
25/04/2018
Company Fully Repays Outstanding Convertible Debt and Avoids Dilution to Stockholders LAS VEGAS, April 25, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company,” “CV Sciences,” “our” or “we”) announced [...]
Tauriga Sciences Inc. to Present at European Institutional Investor Conference on June 21, 2018 in Berlin, Germany; Venue is the Representative Office of Baden-Wurttemberg in Berlin
25/04/2018
NEW YORK, NY, April 25, 2018 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTC PINK: TAUG ) ("Tauriga" or the "Company"), engaged in building its business through the development, distribution, and licensing of [...]
Tauriga Sciences Inc. Board of Directors Approves 1 for 75 Reverse Split, Reducing Its Outstanding Common Stock to Approximately 52,300,000 Shares With a Proportional Reduction of Its Authorized Common Stock to 100,000,000 Shares
25/04/2018
NEW YORK, NY, April 25, 2018 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTC PINK: TAUG ) ("Tauriga" or the "Company"), engaged in building its business through the development, distribution, and licensing of [...]
Scythian Biosciences Corp. Announces the Appointment of European Cannabis Leader Rob Reid of Prohibition Partners as CEO
25/04/2018
– In addition Scythian announces Liberty Health Sciences CEO George Scorsis as Chairman of the Board and Welcomes Back Rogers Communications Executive Roger Rai to the Board TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- [...]
Progyny and RESOLVE to Ring the Nasdaq Stock Market Closing Bell in Recognition of National Infertility Awareness Week®
25/04/2018
New York City, April 25, 2018 (GLOBE NEWSWIRE) -- Progyny, the leading fertility benefits management company, and RESOLVE: The National Infertility Association announced today they will ring the Nasdaq Stock Market [...]
Teladoc Announces U.S. Launch of Behavioral Health Navigator
25/04/2018
First Comprehensive Suite of Telebehavioral Health Services Improves Accuracy, Care Coordination and Access, to Drive Improved Outcomes PURCHASE, NY, April 25, 2018 (GLOBE NEWSWIRE) -- Teladoc , Inc. (NYSE: TDOC ), the [...]
Cesca Therapeutics Inc. to Exhibit at Several Upcoming Cell Therapy Conferences
25/04/2018
RANCHO CORDOVA, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ: KOOL ) today announced that the Company will be exhibiting its full suite of cellular processing [...]
Sientra to Showcase OPUS™ Breast Products and miraDry fresh™ Procedure at American Society of Aesthetic Plastic Surgeons Meeting
25/04/2018
Unveils Sientra Platinum20™ Best in Class Warranty Program for OPUS Breast Implants Announces Preliminary Unaudited First Quarter 2018 Net Sales of Approximately $14.5 Million SANTA BARBARA, Calif., April 25, 2018 ( [...]
Profound Medical to Present at the 2018 Bloom Burton & Co. Healthcare Investor Conference
25/04/2018
TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V: PRN ) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time [...]
Ascendis Pharma A/S Announces Upcoming Investor Presentations
25/04/2018
COPENHAGEN, Denmark, April 25, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND ), a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address significant unmet [...]
Alder BioPharmaceuticals® New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals (Up to 32.5 days) and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine
25/04/2018
Patients with a 75% or greater response experienced an eight-fold increase in migraine-free days and more meaningful improvements in bodily pain and physical function BOTHELL, Wash., April 25, 2018 (GLOBE NEWSWIRE) -- [...]
Targovax ASA: Issuance of restricted stock units (RSUs) to the board members
25/04/2018
Reference is made to the annual general meeting of Targovax ASA (the "Company") on 11 April 2018 (the "AGM") where election of members to the board of directors was according to the nomination committee's proposal. At [...]
GTX Corp Sponsor and Presenter at the Safe America World Safe Symposium
25/04/2018
Patrick Bertagna GTX Corp CEO nominated to join the Safe America Board LOS ANGELES, April 25, 2018 (GLOBE NEWSWIRE) -- GTX Corp (OTCBB: GTXO ) , an Internet of Things (IoT) solutions provider in the personal location, [...]
Extendicare Announces Closing of Underwriters' $16.5 Million Over-Allotment Option of 5.00% Convertible Debentures
25/04/2018
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES MARKHAM, Ontario, April 25, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE ) announced today that it [...]
Asklepios BioPharmaceutical, Inc. Announces Former Portfolio Company’s Preclinical Asset for Duchenne Muscular Dystrophy Has Advanced into the Clinic
25/04/2018
Pfizer, Inc. Dosed First Patient in its Mini-Dystrophin Gene Therapy Phase 1b Trial Another AskBio Platform Product to be Acquired by Big Pharma Novartis CHAPEL HILL, N.C., April 25, 2018 (GLOBE NEWSWIRE) -- Asklepios [...]
Achaogen to Host Conference Call and Webcast of First Quarter 2018 Financial Results on May 4, 2018
25/04/2018
SOUTH SAN FRANCISCO, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO ), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram- [...]
AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3
25/04/2018
CHICAGO, April 25, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ: AVXS ), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, [...]

Pages